A Multi-Dose Study With a Treatment for Open-Angle Glaucoma

Alcon

Status and phase: Withdrawn; Phase 3; Phase 2

Conditions: Open-Angle Glaucoma

Treatments: Drug: Anecortave Acetate; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00705770

C-07-58

Details and patient eligibility

About

The purpose of this study is to determine whether Anecortave Acetate is effective for lowering intraocular pressure caused by open-angle glaucoma.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients at least 18 years old with a clinical diagnosis of Open-Angle Glaucoma for at least 6 months and currently treated with a monotherapy hypotensive medication

Exclusion criteria

• Prior angle surgery in the study eye, severe visual field loss in either eye, and any other form of glaucoma besides open-angle glaucoma

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

0 participants in 4 patient groups, including a placebo group

1

Placebo Comparator group

Description:

Placebo treatment with vehicle

Treatment:

Drug: Placebo

2

Experimental group

Description:

Low dose of study medication

Treatment:

Drug: Anecortave Acetate

Drug: Anecortave Acetate

Drug: Anecortave Acetate

3

Experimental group

Description:

Middle dose of study medication

Treatment:

Drug: Anecortave Acetate

Drug: Anecortave Acetate

Drug: Anecortave Acetate

4

Experimental group

Description:

High dose of study medication

Treatment:

Drug: Anecortave Acetate

Drug: Anecortave Acetate

Drug: Anecortave Acetate